Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 12/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.49 |
| ▸ | GLA | P06280 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CDC42 | P60953 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4020100 | 0.91 | PTGS2 (0.52) | PDE5APTGS2PTGS1CA1CA2 | |
| SCHEMBL4025696 | 0.90 | PDE5A (0.52) | PDE5APTGS2PTGS1ALDH1A1MAPT | |
| SCHEMBL27678565 | 0.90 | PTGS2 (0.60) | PDE5APTGS2PTGS1 | |
| SCHEMBL4021459 | 0.90 | PDE5A (0.51) | PDE5APTGS2PTGS1CA1CA2 | |
| SCHEMBL4023890 | 0.90 | PDE5A (0.59) | PDE5APTGS2PTGS1L3MBTL1 | |
| SCHEMBL4019101 | 0.89 | PDE5A (0.50) | PDE5APTGS2PTGS1CA1CA2 | |
| SCHEMBL4020475 | 0.89 | PDE5A (0.50) | PDE5APTGS2PTGS1L3MBTL1 | |
| SCHEMBL4023933 | 0.86 | PTGS2 (0.53) | PDE5APTGS2PTGS1CA1CA2 | |
| SCHEMBL4024652 | 0.86 | PDE5A (0.47) | PDE5APTGS2PTGS1 | |
| SCHEMBL4020479 | 0.86 | MAPT (0.57) | PDE5APTGS2PTGS1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504519-B2 | Derivatives of pyrazoline, procedure for obtaining them and use thereof as therapeutic agents | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-03-17 | — | — | US | claimed |
| JP-2008506680-A | — | — | 2008-03-06 | — | — | JP | claimed |
| US-20080021084-A1 | Derivatives Of Pyrazoline, Procedure For obtaining Them And Use Thereof As Therapeutic Agents | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-01-24 | — | — | US | claimed |
| CN-101018771-A | Derivatives of pyrazoline, procedure for obtaining them and use thereof as therapeutic agents | ESTEVE LABOR DR (ES) | 2007-08-15 | — | — | CN | claimed |
| EP-1773782-A1 | DERIVATIVES OF PYRAZOLINE, PROCEDURE FOR OBTAINING THEM AND USE THEREOF AS THERAPEUTIC AGENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-04-18 | — | — | EP | claimed |
| WO-2006011005-A1 | DERIVATIVES OF PYRAZOLINE, PROCEDURE FOR OBTAINING THEM AND USE THEREOF AS THERAPEUTIC AGENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-02-02 | — | — | WO | claimed |
| US-7504519-B2 | Derivatives of pyrazoline, procedure for obtaining them and use thereof as therapeutic agents | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-03-17 | — | — | US | disclosed |
| US-20080021084-A1 | Derivatives Of Pyrazoline, Procedure For obtaining Them And Use Thereof As Therapeutic Agents | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-01-24 | — | — | US | disclosed |
| CN-101018771-A | Derivatives of pyrazoline, procedure for obtaining them and use thereof as therapeutic agents | ESTEVE LABOR DR (ES) | 2007-08-15 | — | — | CN | disclosed |
| EP-1773782-A1 | DERIVATIVES OF PYRAZOLINE, PROCEDURE FOR OBTAINING THEM AND USE THEREOF AS THERAPEUTIC AGENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006011005-A1 | DERIVATIVES OF PYRAZOLINE, PROCEDURE FOR OBTAINING THEM AND USE THEREOF AS THERAPEUTIC AGENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021084-A1 | Derivatives Of Pyrazoline, Procedure For obtaining Them And Use Thereof As Therapeutic Agents | CYP3A5, HRH2, PTGS1 | PDE5A 346/4885PTGS2 44/4885PTGS1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.